Patents Assigned to UNIVERSITY HEALTH NETWORKS
  • Patent number: 10494426
    Abstract: The invention provides antibodies that specifically bind to transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: December 3, 2019
    Assignees: PROTHENA BIOSCIENCES LIMITED, UNIVERSITY HEALTH NETWORK
    Inventors: Tarlochan S. Nijjar, Avijit Chakrabartty, Jeffrey N. Higaki
  • Patent number: 10497113
    Abstract: Embodiments disclose a method performed by at least one processor for processing a plurality of x-ray projection images of a subject, the method comprising a plurality of operations including reconstructing the projection images to yield a volume reconstruction; segmenting the reconstructed volume by assigning a material type to each voxel; estimating a first set of scatter images corresponding to a subset of the projection images by calculating probabilistic predictions of interactions of x-rays with the subject and applying a low pass spatial filter to the scatter images; estimating a second set of scatter images corresponding to projection images not included in the subset, based on the first set of scatter images; and subtracting, for each projection image, the corresponding scatter image to yield a corrected projection image.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: December 3, 2019
    Assignees: Elekta AB (publ), University Health Network
    Inventors: Marcus Hennix, Hakan Nordstrom, Markus Eriksson, Jonas Adler, David Jaffray, Gregory Bootsma, Frank Verhaegen, Bjorn Nutti
  • Patent number: 10475537
    Abstract: Methods and systems for evaluating a proposed treatment plan for radiation therapy, for evaluating one or more delineated regions of interest for radiation therapy, and/or for generating a proposed treatment plan for radiation therapy. Machine learning based on historical data may be used.
    Type: Grant
    Filed: June 12, 2014
    Date of Patent: November 12, 2019
    Assignee: University Health Network
    Inventors: Thomas G. Purdie, Christopher James McIntosh, Igor Svistoun
  • Patent number: 10472353
    Abstract: A fumarate salt and a maleate salt of compound (I) represented by the following structural formula, as well as their corresponding pharmaceutical compositions, are disclosed. Particular single crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are also disclosed. The present invention also provides methods of treating a subject with a cancer.
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: November 12, 2019
    Assignee: University Health Network
    Inventors: Peter Brent Sampson, Miklos Feher, Heinz W. Pauls
  • Patent number: 10464999
    Abstract: The invention provides antibodies that specifically bind transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.
    Type: Grant
    Filed: July 2, 2016
    Date of Patent: November 5, 2019
    Assignees: PROTHENA BIOSCIENCES LIMITED, UNIVERSITY HEALTH NETWORK
    Inventors: Yue Liu, Tarlochan S. Nijjar, Avijit Chakrabartty, Jeffrey N. Higaki
  • Publication number: 20190322986
    Abstract: The present invention relates to in vitro methods of enriching populations of human pluripotent stem cells that are induced to differentiate to cardiomyocyte progenitor cells and cardiomyocyte cells. The cell populations can be enriched by isolating cells that express SIRPA. The invention also related to in vitro-enriched populations of cardiomyocyte cells and cardiomyocyte progenitor cells obtained from populations of pluripotent stem.
    Type: Application
    Filed: May 11, 2018
    Publication date: October 24, 2019
    Applicant: UNIVERSITY HEALTH NETWORK
    Inventors: Gordon Keller, April M. Craft, Nicole C. Dubois
  • Patent number: 10441668
    Abstract: Various embodiments are described herein for a system and a method for identifying a region of interest in tissue using mass spectrometry. An agent administration component can be provided to administer an exogenous agent to the tissue. A sampling unit can also be provided to acquire a sample from the tissue. The sample can then be provided to a high sensitivity analysis platform, such as a mass analyzer, to analyze the sample and determine a distribution of the exogenous agent or a by-product of the exogenous agent within the tissue based on the analysis. The analysis platform can then identify the region of interest based on the distribution of the exogenous agent or the distribution of the by-product.
    Type: Grant
    Filed: December 8, 2015
    Date of Patent: October 15, 2019
    Assignee: University Health Network
    Inventors: Arash Zarrine-Afsar, David Anthony Jaffray
  • Patent number: 10438356
    Abstract: Systems and methods for determining bacterial load in targets and tracking changes in bacterial load of targets over time are disclosed. An autofluorescence detection and collection device includes a light source configured to directly illuminate at least a portion of a target and an area around the target with excitation light causing at least one biomarker in the illuminated target to fluoresce. Bacterial autofluorescence data regarding the illuminated portion of the target and the area around the target is collected and analyzed to determine bacterial load of the illuminated portion of the target and area around the target. The autofluorescence data may be analyzed using pixel intensity. Changes in bacterial load of the target over time may be tracked. The target may be a wound in tissue.
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: October 8, 2019
    Assignee: UNIVERSITY HEALTH NETWORK
    Inventor: Ralph Dacosta
  • Patent number: 10407915
    Abstract: A locking member for a gate apparatus comprises a body mountable to a gripping array of a support, said body having a mating form mutually engageable with the gripping array, whereby axial motion of said body relative to said gripping array is inhibited. A member extends away from said body, said member defining a cross-tie mount for receiving a mating end of a cross-tie. The cross-tie mount has a cross-tie end retainer which is movable between a first position securing said cross-tie in said cross-tie mount, and a second position permitting release of said cross-tie from said cross-tie mount, whereby the cross-tie may be moved to function as a gate.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: September 10, 2019
    Assignee: University Health Network
    Inventors: Andrew John Hart, Geoffrey Roy Fernie, T. Daniel Smyth, Victoria P. Komisar, Emily Catherine King, Peter George Murray
  • Patent number: 10392374
    Abstract: A fumarate salt and a maleate salt of compound (I) represented by the following structural formula, as well as their corresponding pharmaceutical compositions, are disclosed. Particular single crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are also disclosed. The present invention also provides methods of treating a subject with a cancer.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: August 27, 2019
    Assignee: University Health Network
    Inventors: Peter Brent Sampson, Miklos Feher, Heinz W. Pauls
  • Patent number: 10358436
    Abstract: The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: July 23, 2019
    Assignee: University Health Network
    Inventors: Peter Brent Sampson, Yong Liu, Sze-Wan Li, Bryan T. Forrest, Heinz W. Pauls, Louise G. Edwards, Miklos Feher, Narendra Kumar B. Patel, Radoslaw Laufer
  • Patent number: 10350237
    Abstract: A biocompatible, electrically conductive biomaterial capable of earn carrying the electrical potential of a cardiac impulse and comprising (1) a conductive polymer such as polyaniline, polypyrrole or polythiophene, and (ii) a biocompatible component such as a polysaccharide, a protein, or a polypeptide, in particular chitosan or gelatin, is described. The material can take the form of a hydrogel, membrane, sheet or mesh. It can be used to restore or improve electrical impulse propagation across damaged tissue or scar region of the myocardium, in particular in the ti treatment of myocardial infarction and arrhythmia.
    Type: Grant
    Filed: February 4, 2014
    Date of Patent: July 16, 2019
    Assignee: University Health Network
    Inventor: Ren-Ke Li
  • Patent number: 10336810
    Abstract: Disclosed herein are chimeric antigen receptors (CARs) comprising an intracellular segment comprising an interleukin receptor chain, a JAK-binding motif, a Signal Transducer and Activator of Transcription (STAT) 5 association motif and/or a CD3? intracellular signaling domain comprising an exogenous STAT3 association motif, as well as cells and 5 compositions comprising said CARs and uses thereof.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: July 2, 2019
    Assignees: University Health Network, Takara Bio Inc.
    Inventors: Shinya Tanaka, Naoto Hirano, Yuki Kagoya
  • Patent number: 10335608
    Abstract: A method for destroying cells and/or microorganisms in an organism includes the following steps: (a) administering to the organism a composition including a photodynamic compound containing at least one transition metal; and (b) irradiating the photodynamic compound in the organism with electromagnetic radiation, wherein the electromagnetic radiation includes ionizing radiation and is effective to activate the photodynamic compound to destroy at least one of the cells and the microorganisms in the organism. The ionizing radiation is preferably X-rays and/or gamma rays. The non-ionizing radiation is preferably light in the range from 600-950 nm.
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: July 2, 2019
    Assignees: THERALASE TECHNOLOGIES, INC., UNIVERSITY HEALTH NETWORK
    Inventors: Arkady Mandel, Carl Fisher, Lothar Lilge
  • Patent number: 10314548
    Abstract: Methods and systems for performing T1 mapping. T1 samples are obtained from an acquisition including one or more inversion groupings. The acquisition may be designed to result in incomplete tissue magnetization recovery between inversion groupings. The acquisition may be designed for the use of non-uniform, non-180° preparatory pulses. The method may also include the combined use of data from different inversion groupings. A model is used in which fit parameters are variable dependent on the inversion grouping.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: June 11, 2019
    Assignee: University Health Network
    Inventors: Marshall Stephen Sussman, Bernd Juergen Wintersperger, Kai-Ho Fok, Issac Yiqun Yang
  • Patent number: 10307428
    Abstract: Compositions for therapy of a diabetic symmetrical polyneuropathy a subject in need thereof, the compositions comprising: an effective amount of a muscarinic acetylcholine receptor antagonist exemplified by pirenzepine, telenzepine, atropine, or derivatives thereof or salts thereof or analogs thereof or derivatives thereof, and a pharmacologically acceptable carrier. The composition may be injectable or alternatively, may be applied topically or alternatively, may be delivered orally. A suitable topical composition may comprise a lotion, a cream, a gel, or a viscous fluid. The muscarinic acetylcholine receptor antagonist may be a muscarinic acetylcholine receptor antagonist salt or a muscarinic acetylcholine receptor antagonist derivative or a muscarinic acetylcholine receptor antagonist analog.
    Type: Grant
    Filed: October 24, 2011
    Date of Patent: June 4, 2019
    Assignees: University Health Network, University of Manitoba, The Regents of The University of California
    Inventors: Paul Fernyhough, Nigel A. Calcutt, Lakshmi Kotra
  • Publication number: 20190144848
    Abstract: There is described herein, a method of capturing cell-free methylated DNA from a sample having less than 100 mg of cell-free DNA, comprising the steps of: subjecting the sample to library preparation to permit subsequent sequencing of the cell-free methylated DNA; adding a first amount of filler DNA to the sample, wherein at least a portion of the filler DNA is methylated; denaturing the sample; and capturing cell-free methylated DNA using a binder selective for methylated polynucleotides.
    Type: Application
    Filed: May 3, 2017
    Publication date: May 16, 2019
    Applicant: UNIVERSITY HEALTH NETWORK
    Inventors: Daniel Diniz DE CARVALHO, Shu Yi SHEN, Rajat SINGHANIA
  • Patent number: 10278639
    Abstract: Described herein are various embodiments of a method and system for sleep detection. For example, in one embodiment, a method is described for automatically characterizing digitized breath sounds recorded from a subject over time as indicative of the subject being one of asleep and awake. This method comprises identify individual breathing cycles in a given segment of the recorded breath sounds; calculating one or more preset breathing cycle characteristics from the identified breathing cycles; evaluating a relative regularity of the calculated characteristics for the given segment; and upon the relative regularity satisfying a preset high regularity condition, outputting a sleep status indicator that the subject was likely asleep during the segment, otherwise outputting a wake indicator that the subject was likely awake during the segment.
    Type: Grant
    Filed: April 23, 2015
    Date of Patent: May 7, 2019
    Assignee: University Health Network
    Inventors: Hisham Alshaer, T. Douglas Bradley
  • Publication number: 20190111086
    Abstract: A method for generating chondrocytes and/or cartilage, optionally articular like non-hypertrophic chondrocyte cells and/or cartilage like tissue and/or hypertrophic chondrocyte like cells and/or cartilage like tissue, the method comprising: a. culturing a primitive streak-like mesoderm population, optionally a CD56+, PDGFRalpha+ KDR? primitive streak-like mesoderm population, with a paraxial mesoderm specifying cocktail comprising: i. a FGF agonist; ii. a BMP inhibitor; optionally Noggin, LDN-193189, Dorsomorphin; and iii. optionally one or more of a TGFbeta inhibitor, optionally SB431524; and a Wnt inhibitor, optionally DKK1, IWP2, or XAV939; to specify a paraxial mesoderm population expressing cell surface CD73, CD105 and/or PDGFR-beta; b. generating a chondrocyte precursor population comprising: i. culturing the paraxial mesoderm population expressing CD73, CD105 and/or PDGFR-beta at a high cell density optionally in serum free or serum containing media; ii.
    Type: Application
    Filed: May 11, 2018
    Publication date: April 18, 2019
    Applicant: UNIVERSITY HEALTH NETWORK
    Inventors: Gordon KELLER, April M. CRAFT
  • Patent number: 10258653
    Abstract: Compositions and methods for delivering immune modulatory molecules to result in a therapeutic effect are disclosed. The compositions and methods use stably integrating lentiviral delivery systems. The methods are useful for therapeutically and prophylactically treating cancer such as leukemia.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: April 16, 2019
    Assignee: University Health Network
    Inventors: Jeffrey A. Medin, Christopher J. Paige